These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10378514)

  • 1. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.
    Sier CF; Sidenius N; Mariani A; Aletti G; Agape V; Ferrari A; Casetta G; Stephens RW; Brünner N; Blasi F
    Lab Invest; 1999 Jun; 79(6):717-22. PubMed ID: 10378514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
    Sier CF; Nicoletti I; Santovito ML; Frandsen T; Aletti G; Ferrari A; Lissoni A; Giavazzi R; Blasi F; Sidenius N
    Thromb Haemost; 2004 Feb; 91(2):403-11. PubMed ID: 14961171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
    Begum FD; Høgdall EV; Riisbro R; Christensen IJ; Engelholm SA; Jørgensen M; Pedersen BN; Høgdall CK
    APMIS; 2006 Oct; 114(10):675-81. PubMed ID: 17004970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
    Casella R; Shariat SF; Monoski MA; Lerner SP
    Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
    Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
    J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
    Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
    Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.